Dice CEO: Energy, T...
Health Care: Health Services
Enzo Biochem Inc. (ENZ: NYSE)
$1.79 -0.03 | -1.65%
06/01/12 - 04:03 PM ET
Company Balance Sheet
| Jul 2011 | Jul 2010 | Jul 2009 | Jul 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 14.16M | 8.76M | 6.93M | 78.32M |
| Receivables | 15.24M | 13.01M | 12.48M | 15.35M |
| Inventories | 9.26M | 8.88M | 9.26M | 9.51M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 51.40M | 57.74M | 74.46M | 105.68M |
| Property, Plant & Equipment, Gross | 31.19M | 29.46M | 27.24M | 21.81M |
| Accumulated Depreciation & Depletion | 20.86M | 17.61M | 15.92M | 12.76M |
| Property, Plant & Equipment, Net | 10.34M | 11.86M | 11.32M | 9.05M |
| Intangibles | 19.98M | 20.37M | 22.01M | 17.66M |
| Other Non-Current Assets | 382.00K | 338.00K | 439.00K | 812.00K |
| Total Non-Current Assets | 58.08M | 57.51M | 58.67M | 48.84M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 109.47M | 115.24M | 133.13M | 154.52M |
| Accounts Payable | 7.86M | 6.46M | 4.24M | 4.30M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.68M | 572.00K | 1.06M | 72.00K |
| Total Current Liabilities | 17.73M | 15.56M | 13.94M | 13.29M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 2.93M | 2.58M | 2.37M | 2.43M |
| Other Non-Current Liabilities | 96.00K | 90.00K | 38.00K | 512.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 3.03M | 2.67M | 2.40M | 2.94M |
| Total Liabilities | 20.76M | 18.23M | 16.35M | 16.23M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 88.72M | 97.02M | 116.78M | 138.29M |
| Common Par | 390.00K | 388.00K | 386.00K | 380.00K |
| Additional Paid In Capital | 305.83M | 306.56M | 306.28M | 303.81M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 1.59M |
| Retained Earnings | -214.91M | -201.95M | -179.72M | -156.16M |
| Treasury Stock | -6.39M | -8.85M | -10.44M | -11.33M |
| Other Equity Adjustments | 3.79M | 875.00K | 276.00K | 0.00 |
| Total Capitalization | 88.72M | 97.02M | 116.78M | 138.29M |
| Total Equity | 88.72M | 97.02M | 116.78M | 138.29M |
| Total Liabilities & Stock Equity | 109.47M | 115.24M | 133.13M | 154.52M |
| Total Common Shares Outstanding | 38.60M | 38.16M | 38.59M | 37.23M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 450.01K | 623.85K | 735.55K | 777.72K |
| Basic Weighted Shares Outstanding | 38.36M | 38.00M | 37.51M | 36.88M |
| Diluted Weighted Shares Outstanding | 38.36M | 38.00M | 37.51M | 36.88M |
| Number of Employees | 535 | 527 | 539 | 439 |
| Number of Part-Time Employees | 71 | 62 | 75 | 71 |
Portfolios with ENZ
- Portfolio NameUser Type
- UserBarron's Insider Purchases ...
- ContributorStockerblog.com Gene Therap...
- Userkelvinenz Portfolio 1
- UserS-0022
- UserTraderSteveUK Portfolio 1
- UserRT_in_CA
- UserSo far, I'm beating the S&a...
- Userjwcarmack Portfolio 1
- Userrecentoutperform070824
- Usersfields Portfolio 1
Latest ENZ Headlines from TheStreet
- Thursday Earnings Live Blog 10.14.10 | 04:10 pm
- Investors May See Upside Down Under 09.16.10 | 08:09 am
- Enzo Biochem 1Q Loss Narrows On Revenue Boost 12.10.09 | 04:12 pm
- Enzo Biochem 4Q Loss Widens On Costs 10.14.09 | 06:10 pm
- Tuesday's Health Winners & Losers 10.16.07 | 04:10 pm
- Enzo Biochem Falls on Court Dismissal 09.07.07 | 02:09 pm
- Friday's Health Winners & Losers 09.07.07 | 02:09 pm
- Checking Up on Biotech 08.10.07 | 04:08 pm
- Monday's Health Winners & Losers 10.16.06 | 02:10 pm
- Enzo Biochem Loss Widens 10.16.06 | 11:10 am
Press Releases for ENZ
- Enzo Biochem Launch Of Test For Measuring Risk Of Colorectal Cancer Underscores Growing Role Of Molecular Diagnostics - Business Wire 04.10.12 | 08:04 am
- Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform Details At ESCMID London Meeting - Business Wire 04.01.12 | 04:04 pm
- Enzo Biochem To Present At Needham Healthcare Conference - Business Wire 03.27.12 | 12:03 pm
- Enzo Biochem Announces Expanded Distribution Agreement With Japan’s Cosmo Bio - Business Wire 03.20.12 | 07:03 am
- Enzo Biochem’s Clinical Laboratory Applies For NY State Health Department Approval For First Assay Based On Its AmpiProbe™ Amplification Platform - Business Wire 03.13.12 | 07:03 am
- Enzo Biochem Reports Improved Second Quarter Results - Business Wire 03.12.12 | 04:03 pm
- Enzo Biochem To Present New AmpiProbe™ Nucleic Acid Amplification Platform At ESCMID London Meeting - Business Wire 03.08.12 | 08:03 am
- Enzo Biochem Schedules Teleconference To Discuss 2012 Second Quarter Results On March 13, 2012 At 8:30 AM E.T. - Business Wire 03.08.12 | 07:03 am
- Enzo Biochem Receives Approval For Novel Blood Based Test For Colorectal Cancer Risk - Business Wire 02.21.12 | 08:02 am
- Enzo Biochem To Present At 2012 Leerink Swann Global Healthcare Conference - Business Wire 02.10.12 | 12:02 pm
Partner Headlines for ENZ
- Investors Should Wait Out Quest & LabCorp - Seeking Alpha 02.16.12 | 09:02 am
- Enzo Biochem: Personalized Medicine Is More Than Targeted Therapeutics - Seeking Alpha 04.03.11 | 07:04 am
- Competitive Technologies: Short Squeeze Coming or Another Leg Down? - Seeking Alpha 08.25.10 | 09:08 am
- Top 5 Percentage Gainers On NYSE (DV, CKH, ENZ, LAD, CMG) - Benzinga 07.23.10 | 03:07 pm
- MB FINANCL INC (MBFI) - Profit Tracks - Zacks 04.13.10 | 01:04 am
- UPDATE 2-Enzo wins round in Applera patent fight - Reuters 03.26.10 | 04:03 pm
